Table 1. Patient, tumor, and treatment characteristics across treatment eras.
| Characteristics | All patients (n=50) | 2003–2010 (n=20) | 2011–2018 (n=30) | p-value | |
|---|---|---|---|---|---|
| Age | 70 (28–85) | 70.5 (28–83) | 70 (40–85) | 0.606 | |
| Race | |||||
| Non-hispanic white | 34 (68) | 12 (60) | 22 (73.3) | 0.495 | |
| Non-hispanic black | 13 (26) | 7 (35) | 6 (20) | - | |
| Hispanic | 3 (6) | 1 (5) | 2 (6.7) | - | |
| BMI | 0.763 | ||||
| <30 | 25 (50) | 9 (45) | 16 (53.3) | ||
| 30–40 | 17 (34) | 8 (40) | 9 (30) | ||
| >40 | 8 (16) | 3 (15) | 5 (16.7) | ||
| Cancer history | |||||
| Breast cancer | 8 (16) | 3 (15) | 5 (16.7) | 0.451 | |
| Renal cell carcinoma | 3 (6) | 1 (5) | 2 (6.7) | - | |
| Lung cancer | 2 (4) | 1 (5) | 1 (3.3) | - | |
| AML | 2 (4) | 1 (5) | 1 (3.3) | - | |
| Other | 3 (6) | 1 (5) | 2 (6.7) | - | |
| Tamoxifen use | 3 (6) | 1 (5) | 2 (6.7) | 0.831 | |
| Hormone replacement therapy use | 4 (8) | 2 (10) | 2 (6.7) | 0.505 | |
| Gravidity | 2 (0–9) | 2 (0–9) | 2 (0–5) | 0.204 | |
| Parity | 2 (0–8) | 2 (0–8) | 2 (0–5) | 0.171 | |
| Subtype | |||||
| UPSC | 34 (68) | 14 (70) | 20 (66.7) | 0.804 | |
| Mixed | 16 (32) | 6 (30) | 10 (33.3) | - | |
| Pathologic stage | |||||
| IIIA | 14 (28) | 6 (30) | 8 (26.7) | 0.655 | |
| IIIB | 2 (4) | 0 (0) | 2 (6.7) | - | |
| IIIC1 | 18 (36) | 8 (40) | 10 (30) | - | |
| IIIC2 | 16 (32) | 6 (30) | 10 (33.3) | - | |
| Percentage of myometrial invasion | |||||
| <50% | 19 (38) | 8 (40) | 11 (36.7) | 0.812 | |
| ≥50% | 31 (62) | 12 (60) | 19 (63.3) | - | |
| Percentage depth of myometrial invasion | 65 (0–100) | 63.5 (0–100) | 65.5 (0–100) | 0.779 | |
| Lower uterine segment involved | |||||
| No | 17 (34) | 5 (25) | 12 (40) | 0.236 | |
| Yes | 32 (64) | 15 (75) | 17 (56.7) | - | |
| Unknown | 1 (2) | 0 (0) | 1 (3.3) | - | |
| Cervical involvement | |||||
| No | 31 (62) | 13 (65) | 18 (60) | 0.721 | |
| Yes | 19 (38) | 7 (35) | 12 (40) | - | |
| Lymphovascular space invasion | |||||
| No | 18 (36) | 9 (45) | 9 (30) | 0.279 | |
| Yes | 32 (64) | 11 (55) | 21 (70) | - | |
| Uterine serosa involvement | |||||
| No | 40 (80) | 17 (85) | 23 (76.7) | 0.613 | |
| Yes | 9 (18) | 3 (15) | 6 (20) | - | |
| Unknown | 1 (2) | 0 (0) | 1 (3.3) | - | |
| Fallopian tube involvement | |||||
| No | 35 (70) | 12 (60) | 23 (76.7) | 0.208 | |
| Yes | 15 (30) | 8 (40) | 7 (23.3) | - | |
| Ovary involvement | |||||
| No | 39 (78) | 15 (75) | 24 (80) | 0.676 | |
| Yes | 11 (22) | 5 (25) | 6 (20) | - | |
| Pelvic nodes removed | |||||
| No | 1 (2) | 0 (0) | 1 (3.3) | 0.409 | |
| Yes | 49 (98) | 20 (100) | 29 (96.7) | - | |
| No. of pelvic nodes removed | |||||
| 0 | 1 (2) | 0 (0) | 1 (3.3) | 0.157 | |
| 1–10 | 12 (24) | 4 (20) | 8 (26.7) | - | |
| 11–20 | 23 (46) | 7 (35) | 16 (53.3) | - | |
| 21+ | 14 (28) | 9 (45) | 5 (16.7) | - | |
| Sentinel pelvic node biopsy performed | 0.012 | ||||
| No | 42 (84) | 20 (100) | 22 (73.3) | ||
| Yes | 8 (16) | 0 (0) | 8 (26.7) | ||
| Pelvic nodes involved | |||||
| No | 23 (46) | 10 (50) | 13 (43.3) | 0.643 | |
| Yes | 27 (54) | 10 (50) | 17 (56.7) | - | |
| Para-aortic nodes removed | |||||
| No | 11 (22) | 2 (10) | 9 (30) | 0.094 | |
| Yes | 39 (78) | 18 (90) | 21 (70) | - | |
| No. of para-aortic nodes removed | |||||
| 0 | 11 (22) | 2 (10) | 9 (30) | 0.143 | |
| 1–5 | 25 (50) | 10 (50) | 15 (50) | - | |
| 6+ | 14 (28) | 8 (40) | 6 (20) | - | |
| Para-aortic nodes involved | |||||
| No | 34 (68) | 13 (65) | 21 (70) | 0.710 | |
| Yes | 16 (32) | 7 (35) | 9 (30) | - | |
| Gross tumor size (cm) | 3.75 (0–15) | 4 (3–6) | 3.5 (2–5) | 0.801 | |
| Pelvic washing with malignant cells | |||||
| No | 35 (70) | 17 (85) | 18 (60) | 0.214 | |
| Yes | 11 (22) | 3 (15) | 8 (26.7) | - | |
| Unknown | 4 (8) | 0 (0) | 4 (13.3) | - | |
| Surgery type | |||||
| Open | 28 (56) | 15 (75) | 13 (43.3) | 0.027 | |
| Minimally invasive | 22 (44) | 5 (25) | 17 (56.7) | - | |
| Days to imaging | |||||
| Less than 30 days after surgery | 24 (48) | 6 (30) | 19 (63.3) | 0.044 | |
| More than 30 days after surgery | 24 (48) | 12 (60) | 11 (36.67) | - | |
| Unknown | 2 (4) | 2 (10) | 0 (0) | - | |
| HER2/neu status | |||||
| Positive | 31 (62) | 10 (50) | 21 (70) | 0.001 | |
| Negative | 9 (18) | 1 (5) | 8 (26.7) | - | |
| Unknown | 10 (20) | 9 (45) | 1 (3.3) | - | |
| Herceptin use | 4 (8) | 0 (0) | 4 (13.3) | 0.083 | |
| RT modality | |||||
| VB | 39 (78) | 19 (95) | 20 (66.7) | 0.048 | |
| EBRT | 5 (10) | 1 (5) | 4 (13.3) | - | |
| EBRT + VB | 6 (12) | 0 (0) | 6 (20) | - | |
Values are presented as number (%).
AML, acute myeloid leukemia; BMI, body mass index; EBRT, external beam radiotherapy; HER2, human epidermal growth factor receptor 2; RT, radiotherapy; UPSC, uterine papillary serous carcinoma; VB, vaginal brachytherapy.